Nchi: Marekani
Lugha: Kiingereza
Chanzo: NLM (National Library of Medicine)
VENLAFAXINE HYDROCHLORIDE (UNII: 7D7RX5A8MO) (VENLAFAXINE - UNII:GRZ5RCB1QG)
Zydus Pharmaceuticals USA Inc.
VENLAFAXINE HYDROCHLORIDE
VENLAFAXINE 37.5 mg
ORAL
PRESCRIPTION DRUG
Venlafaxine hydrochloride extended-release capsules are indicated in adults for the treatment of: - Major Depressive Disorder (MDD) [see Clinical Studies (14.1)] - Generalized Anxiety Disorder (GAD) [see Clinical Studies (14.2)] - Social Anxiety Disorder (SAD) [see Clinical Studies (14.3)] - Panic Disorder (PD) [see Clinical Studies (14.4)] Venlafaxine hydrochloride extended-release capsules is contraindicated in patients: - with known hypersensitivity to venlafaxine hydrochloride, desvenlafaxine succinate or to any excipients in the formulation [see Adverse Reactions (6.2)] . - taking, or within 14 days of stopping, MAOIs (including the MAOIs linezolid and intravenous methylene blue) because of the risk of serotonin syndrome [see Dosage and Administration (2.11), Warnings and Precautions (5.2), and Drug Interactions (7.1)] . Pregnancy Exposure Registry There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to antidepressants, including venlafaxine hydrochloride extended-rele
Venlafaxine Hydrochloride Extended-Release Capsules USP, 37.5 mg are white to off-white free flowing pellets filled in size '3' hard gelatin capsules with grey colored cap printed with "ZA-35" in black ink & white body printed with "37.5 mg" in black ink and are supplied as follows: NDC 68382-034-06 in bottle of 30 capsules with child-resistant closure NDC 68382-034-16 in bottle of 90 capsules with child-resistant closure NDC 68382-034-10 in bottle of 1,000 capsules Venlafaxine Hydrochloride Extended-Release Capsules USP, 75 mg are white to off-white free flowing pellets filled in size '1' hard gelatin capsules with peach colored cap printed with "ZA-36" in black ink & white body printed with "75 mg" in black ink and are supplied as follows: NDC 68382-035-06 in bottle of 30 capsules with child-resistant closure NDC 68382-035-16 in bottle of 90 capsules with child-resistant closure NDC 68382-035-10 in bottle of 1,000 capsules Venlafaxine Hydrochloride Extended-Release Capsules USP, 150 mg are white to off-white free flowing pellets filled in size '0' hard gelatin capsules with dark orange colored cap printed with "ZA-37" in black ink & white body printed with "150 mg" in black ink and are supplied as follows: NDC 68382-036-06 in bottle of 30 capsules with child-resistant closure NDC 68382-036-16 in bottle of 90 capsules with child-resistant closure NDC 68382-036-10 in bottle of 1,000 capsules Store at 20°C to 25°C (68°F to 77°F) [See USP Controlled Room Temperature]. Dispense in a tight container.
Abbreviated New Drug Application
Zydus Pharmaceuticals USA Inc. ---------- SPL MEDGUIDE Medication Guide Venlafaxine Hydrochloride (ven" la fax' een hye" droe klor' ide) Extended-Release Capsules, USP What is the most important information I should know about venlafaxine hydrochloride extended-release capsules? Venlafaxine hydrochloride extended-release capsules may cause serious side effects, including: Increased risk of suicidal thoughts and actions. Venlafaxine hydrochloride extended-release capsules and other antidepressant medicines may increase suicidal thoughts and actions in some children, adolescents, and young adults, especially within the first few months of treatment or when the dose is changed. Venlafaxine hydrochloride extended-release capsules is not for use in children. • Depression or other serious mental illnesses are the most important causes of suicidal thoughts or actions. How can I watch for and try to prevent suicidal thoughts and actions in myself or a family member? • Pay close attention to any changes, especially sudden changes, in mood, behaviors, thoughts, or feelings. This is very important when an antidepressant medicine is started or when the dose is changed. • Call your healthcare provider right away to report new or sudden changes in mood, behavior, thoughts, or feelings. • Keep all follow-up visits with your healthcare provider as scheduled. Call your healthcare provider between visits as needed, especially if you have concerns about symptoms. Call your healthcare provider or get emergency help right away if you or a family member have any of the following symptoms, especially if they are new, worse, or worry you: • attempts to commit suicide • thoughts about suicide or dying • acting aggressive, being angry, or violent • acting on dangerous impulses • new or worse depression • new or worse anxiety • panic attacks • feeling very agitated or restless • new or worse irritability • trouble sleeping • an extreme increase in activity or talking (mania) • other unusual changes in behavi Soma hati kamili
VENLAFAXINE HYDROCHLORIDE - VENLAFAXINE HYDROCHLORIDE CAPSULE, EXTENDED RELEASE ZYDUS PHARMACEUTICALS USA INC. ---------- HIGHLIGHTS OF PRESCRIBING INFORMATION THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE VENLAFAXINE HYDROCHLORIDE EXTENDED-RELEASE CAPSULES SAFELY AND EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR VENLAFAXINE HYDROCHLORIDE EXTENDED-RELEASE CAPSULES. VENLAFAXINE HYDROCHLORIDE EXTENDED-RELEASE CAPSULES, FOR ORAL USE INITIAL U.S. APPROVAL: 1997 WARNING: SUICIDAL THOUGHTS AND BEHAVIORS ANTIDEPRESSANTS INCREASED THE RISK OF SUICIDAL THOUGHTS AND BEHAVIOR IN PEDIATRIC AND YOUNG ADULT PATIENTS IN SHORT-TERM STUDIES. CLOSELY MONITOR ALL ANTIDEPRESSANT-TREATED PATIENTS FOR CLINICAL WORSENING AND EMERGENCE OF SUICIDAL THOUGHTS AND BEHAVIORS _[SEE_ _WARNINGS AND PRECAUTIONS (5.1)]_ . VENLAFAXINE HYDROCHLORIDE EXTENDED-RELEASE CAPSULES ARE NOT APPROVED FOR USE IN PEDIATRIC PATIENTS _[SEE USE IN SPECIFIC POPULATIONS (8.4)]._ RECENT MAJOR CHANGES Boxed Warning 8/2022 Dosage and Administration (2.10) 11/2021 Dosage and Administration (2.2, 2.3, 2.6, 2.8, 2.9, 2.11) 8/2022 Warnings and Precautions (5.13) 9/2021 Warnings and Precautions (5.7) 11/2021 Warnings and Precautions (5.1, 5.2, 5.4, 5.5, 5.6, 5.7, 5.8) 8/2022 INDICATIONS AND USAGE Venlafaxine hydrochloride extended-release capsules are a serotonin and norepinephrine reuptake inhibitor (SNRI) indicated for the treatment of adults with: Major Depressive Disorder (MDD) (1) Generalized Anxiety Disorder (GAD) (1) Social Anxiety Disorder (SAD) (1) Panic Disorder (PD) (1) DOSAGE AND ADMINISTRATION INDICATION STARTING DOSE TARGET DOSE MAXIMUM DOSE MDD (2.2) 37.5 mg/day to 75 mg/day 75 mg/day 225 mg/day GAD (2.3) 37.5 mg/day to 75 mg/day 75 mg/day 225 mg/day SAD (2.4) 75 mg/day 75 mg/day 75 mg/day PD (2.5) 37.5 mg/day 75 mg/day 225 mg/day Take once daily with food. Capsules should be taken whole; do not divide, crush, chew or dissolve (2.1). When discontinuing treatment, reduce the dose gradually (2.10, 5.7). Renal impairment: reduce the tot Soma hati kamili